BLPH Stock: Bellerophon Therapeutics, Inc. Stock Price, Analysis & Insights
Get live blph stock price $0.01, comprehensive Bellerophon Therapeutics, Inc. stock analysis, charts, news, and expert forecast. Real-time blph stock data and investment insights.
Loading chart...
Company Overview
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Company Information
- CEO
- Craig R. Jalbert CIRA
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 18
Contact Information
- Website
- https://bellerophon.com
- Address
- 184 Liberty Corner Road
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.70) may provide portfolio stability
Business Model & Strategy
Bellerophon Therapeutics, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Craig R. Jalbert CIRA, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Bellerophon Therapeutics, Inc. competes in the Biotechnology within the broader Healthcare. With 146791 in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Bellerophon Therapeutics, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Bellerophon Therapeutics, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Bellerophon Therapeutics, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Bellerophon Therapeutics, Inc.
- ⚠Investors should consider how Bellerophon Therapeutics, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
146.79K
P/E Ratio
-0.01
Beta
0.70
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 146.79K market capitalization
- Trading Volume: 1.56K shares traded today
- Price Range: 52-week range of $0.01 - $0.10
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Bellerophon Therapeutics, Inc.
Bellerophon Therapeutics, Inc. (BLPH) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 146.79K, the company represents a significant player in its market. The stock is currently trading at $0.01 with a negativedaily change of 36.84%.
The company's 18 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.01, beta of 0.70, and 52-week price range from $0.01 to $0.10when evaluating investment opportunities.
Why Invest in Bellerophon Therapeutics, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Craig R. Jalbert CIRA
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.